Blb&B Advisors Increases Holding in Bristol Myers Squibb Co (BMY); Knoll Capital Management LP Has Lowered Its Alcobra LTD (ADHD) Holding by $401,449

February 24, 2018 - By Vivian Park

Fred Knoll decreased its stake in Alcobra Ltd (ADHD) by 33.3% based on its latest 2017Q3 regulatory filing with the SEC. Knoll Capital Management Lp sold 401,449 shares as the company’s stock declined 8.00% while stock markets rallied. The hedge fund run by Fred Knoll held 804,049 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $812,000, down from 1.21 million at the end of the previous reported quarter. Knoll Capital Management Lp who had been investing in Alcobra Ltd for a number of months, seems to be less bullish one the $ market cap company. The stock increased 4.29% or $0.42 during the last trading session, reaching $10.22. About 1.11M shares traded or Infinity% up from the average. Alcobra Ltd. – Ordinary Shares (NASDAQ:ADHD) has declined 74.73% since February 24, 2017 and is downtrending. It has underperformed by 91.43% the S&P500.

Blb&B Advisors Llc increased its stake in Bristol Myers Squibb Co (BMY) by 5.53% based on its latest 2017Q3 regulatory filing with the SEC. Blb&B Advisors Llc bought 4,944 shares as the company’s stock declined 1.04% while stock markets rallied. The institutional investor held 94,336 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $6.01 million, up from 89,392 at the end of the previous reported quarter. Blb&B Advisors Llc who had been investing in Bristol Myers Squibb Co for a number of months, seems to be bullish on the $110.93 billion market cap company. The stock increased 3.05% or $2.01 during the last trading session, reaching $67.95. About 5.24M shares traded. Bristol-Myers Squibb Company (NYSE:BMY) has declined 23.19% since February 24, 2017 and is downtrending. It has underperformed by 39.89% the S&P500.

Among 7 analysts covering Alcobra (NASDAQ:ADHD), 2 have Buy rating, 1 Sell and 4 Hold. Therefore 29% are positive. Alcobra had 19 analyst reports since August 9, 2015 according to SRatingsIntel. Jefferies maintained the shares of ADHD in report on Monday, June 12 with “Hold” rating. The firm earned “Underweight” rating on Friday, October 28 by Barclays Capital. The company was initiated on Monday, August 1 by Barclays Capital. The rating was upgraded by Zacks to “Hold” on Monday, August 17. The company was downgraded on Friday, September 29 by Roth Capital. The stock of Alcobra Ltd. – Ordinary Shares (NASDAQ:ADHD) has “Speculative Buy” rating given on Monday, October 9 by WBB Securities. The firm has “Outperform” rating by Oppenheimer given on Monday, January 25. Cantor Fitzgerald downgraded the shares of ADHD in report on Thursday, September 29 to “Hold” rating. The stock of Alcobra Ltd. – Ordinary Shares (NASDAQ:ADHD) earned “Hold” rating by WBB Securities on Wednesday, November 2. WBB Securities maintained the shares of ADHD in report on Sunday, August 9 with “Hold” rating.

Blb&B Advisors Llc, which manages about $669.27 million and $649.25 million US Long portfolio, decreased its stake in Arconic Inc by 15,166 shares to 79,936 shares, valued at $1.99M in 2017Q3, according to the filing. It also reduced its holding in Boeing Co (NYSE:BA) by 1,856 shares in the quarter, leaving it with 24,861 shares, and cut its stake in Mondelez Intl Inc (NASDAQ:MDLZ).

Since September 6, 2017, it had 1 buy, and 2 insider sales for $646,385 activity. Another trade for 5,300 shares valued at $335,172 was sold by Lynch Thomas J. Jr.. 9,340 shares valued at $560,400 were sold by Caldarella Joseph C on Wednesday, September 6.

Among 19 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 7 have Buy rating, 3 Sell and 9 Hold. Therefore 37% are positive. Bristol-Myers Squibb Company had 73 analyst reports since July 28, 2015 according to SRatingsIntel. The rating was maintained by Barclays Capital on Friday, October 13 with “Equal-Weight”. The stock of Bristol-Myers Squibb Company (NYSE:BMY) earned “Hold” rating by Cowen & Co on Thursday, October 19. As per Wednesday, October 18, the company rating was maintained by Citigroup. BMO Capital Markets maintained the shares of BMY in report on Monday, November 13 with “Sell” rating. Citigroup maintained the shares of BMY in report on Tuesday, September 20 with “Buy” rating. As per Friday, July 28, the company rating was maintained by BMO Capital Markets. Robert W. Baird initiated Bristol-Myers Squibb Company (NYSE:BMY) on Wednesday, April 26 with “Outperform” rating. On Thursday, October 26 the stock rating was maintained by Piper Jaffray with “Hold”. The stock of Bristol-Myers Squibb Company (NYSE:BMY) has “Underweight” rating given on Monday, August 24 by Piper Jaffray. The stock of Bristol-Myers Squibb Company (NYSE:BMY) has “Equal Weight” rating given on Friday, April 29 by Barclays Capital.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>